Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AON-D21
- Development stage
- Phase 2
- Lead developer
- Aptarion Biotech
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
AON-D21 is a PEGylated L-configured aptamer, a synthetic oligonucleotide designed to specifically bind and neutralize the complement component C5a. By inhibiting C5a, AON-D21 prevents activation of both C5a receptors, thereby reducing excessive inflammation associated with severe inflammatory conditions. Its primary indication under investigation is severe community-acquired pneumonia, particularly in patients requiring intensive care. The drug is administered intravenously and has reached Phase 2 clinical trials in several European countries. Developed by Aptarion Biotech AG, AON-D21 represents a novel approach to modulating the immune response in acute inflammatory diseases[1][2][3][4][5][6][7].
- Other names
- L-aptamerSpiegelmerPegylated L-configured aptamer
02
Targets
Complement component C5aC5a des-Arg (Complement C5a des-Arg)
Beyond the preview
Go deeper on AON-D21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AON-D21.